Related Experiment Video
Updated: May 28, 2026
16:59
Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer
Published on: October 10, 2012
Polymeric gene delivery for diabetic treatment
1Department of Pharmaceutics and Pharmaceutical Chemistry and Department of Bioengineering, University of Utah, Salt Lake City, UT, USA.
Diabetes & Metabolism Journal
|October 7, 2011
Summary
Novel polymers effectively delivered therapeutic genes, including IL-10 plasmid DNA and Fas siRNA, to combat autoimmune insulitis and halt diabetic progression in animal models.
Area of Science:
- Biomaterials Science
- Immunology
- Endocrinology
Background:
- Type 1 diabetes involves autoimmune destruction of insulin-producing beta cells.
- Gene therapy offers a promising approach to treat autoimmune diabetes.
- Developing effective delivery systems for therapeutic nucleic acids is crucial.
Purpose of the Study:
- To investigate the use of various polymers for gene delivery in diabetic animal models.
- To evaluate the potential of these polymer-gene complexes in preventing or treating autoimmune diabetes.
Main Methods:
- Utilized polyaminobutyl glycolic acid for interleukin-10 (IL-10) plasmid DNA delivery to prevent insulitis in non-obese diabetic (NOD) mice.
- Employed polyethylene glycol-grafted polylysine with antisense glutamic acid decarboxylase (GAD) mRNA to modulate GAD autoantigen expression.
- Administered glucagon-like peptide-1 (GLP1) and exendin-4 (TSTA, SP-EX4) via bioreducible polymers to impede diabetic progression.
- Delivered Fas siRNA using polymers to treat diabetic NOD mice.
Main Results:
- Polymer-based delivery systems were successfully employed for various therapeutic agents.
- Specific polymer formulations targeted key pathways in autoimmune diabetes, including IL-10 delivery, GAD modulation, GLP1/exendin-4 administration, and Fas siRNA treatment.
- These approaches showed potential in addressing different aspects of diabetic pathology in animal models.
Conclusions:
- Polymers represent a versatile platform for gene and nucleic acid delivery in diabetes research.
- Targeted delivery of specific genes and molecules via polymers holds promise for managing autoimmune diabetes.
- Further research into polymer-based therapies could lead to novel treatments for diabetes.
More Related Videos
06:21An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness
Published on: May 7, 2018
11:13Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
Published on: April 7, 2016
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...